Food and Drug Regulations, C.R.C., c. 870

Section C.03.301

Cite as Food and Drug Regulations, C.R.C., c. 870, s. C.03.301 · current to June 17, 2026 · regulation last amended June 17, 2026

Statute Watch

Get an alert when a bill in Parliament would change this section, and every time it moves.

The text

The following definitions apply in this section and in sections C.03.302 to C.03.319. adverse reaction means an undesirable and unintended response in a study subject or other person to a study drug that is caused by the administration of any dose of the study drug. (réaction indésirable) good clinical practices means generally accepted clinical practices that are designed to protect the rights, safety and well-being of study subjects and other persons. (bonnes pratiques cliniques) import means, in respect of a study drug, to import it into Canada for sale for the purpose of a study. (importer) other person means an individual who comes into physical contact with a study subject. (autre personne) protocol means a document that describes the objectives, design, methodology, statistical considerations and organization of a study. (protocole) qualified investigator means the physician and member in good standing of a professional medical association in Canada to whom a sponsor gives the responsibility for the proper conduct of the study at a given study site, who is entitled to practise their profession under the laws of the province where the study site is located. (chercheur qualifié) research ethics board means a body described in section C.03.306. (comité d’éthique de la recherche) serious adverse reaction means an adverse reaction that results in any of the following consequences for the study subject or other person: (a) their in-patient hospitalization or its prolongation; (b) a congenital malformation; (c) persistent or significant disability or incapacity; (d) a life-threatening condition; or (e) death. (réaction indésirable grave) serious unexpected adverse reaction means a serious adverse reaction that is not identified in nature, severity or frequency in the risk information set out on the label of the study drug. (réaction indésirable grave et imprévue) sponsor means a person who is responsible for the conduct of a study. (promoteur) study means a basic clinical research study that involves human subjects and that is described in sections C.03.304 and C.03.305. (étude) study drug means a positron-emitting radiopharmaceutical that is used in a study. (drogue destinée à l’étude) study site means the location where all or part of a study is conducted. (lieu d’étude)
Read the Food and Drug Regulations on the Justice Laws Website ↗

Made under Food and Drugs Act, R.S.C. 1985, c. F-27.

Bills in Parliament that would change this section 0

No bill we hold would amend or repeal this section.